Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Related Citations for PubMed (Select 18835003)

1.

Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.

van Griensven J, Zachariah R, Rasschaert F, Atté EF, Reid T.

Trans R Soc Trop Med Hyg. 2009 Jun;103(6):613-9. doi: 10.1016/j.trstmh.2008.08.015. Epub 2008 Oct 2.

PMID:
18835003
2.

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK.

AIDS. 2006 Oct 24;20(16):2043-50.

PMID:
17053350
3.

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33.

PMID:
12792352
4.

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA; Mitochondrial Toxicity (MITOX) Study Group.

JAMA. 2002 Jul 10;288(2):207-15.

PMID:
12095385
5.

Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.

McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE; Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team.

Clin Infect Dis. 2004 Jan 15;38(2):263-70. Epub 2003 Dec 18.

6.

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, Puiggròs C, Crespo M, Feijoo M, Diaz M, Del Saz SV, Planas M, Sureda D, Falcó V, Ocaña I, Pahissa A.

HIV Clin Trials. 2008 Nov-Dec;9(6):407-17. doi: 10.1310/hct0906-407.

PMID:
19203906
7.

High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.

van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R.

Trans R Soc Trop Med Hyg. 2007 Aug;101(8):793-8. Epub 2007 Apr 30.

PMID:
17467756
9.
10.

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA; Mitochondrial Toxicity Study Group.

AIDS. 2004 Apr 30;18(7):1029-36.

PMID:
15096806
11.

Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.

McComsey GA, Paulsen DM, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, Cherry CL, White-Owen C, Thompson KA, Ross ST, Hernandez JE, Ross LL.

AIDS. 2005 Jan 3;19(1):15-23.

PMID:
15627029
12.

Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.

Cherry CL, Lal L, Thompson KA, McLean CA, Ross LL, Hernandez J, Wesselingh SL, McComsey G.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):263-7.

PMID:
15735442
13.

Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.

Benn P, Sauret-Jackson V, Cartledge J, Ruff C, Sabin CA, Moyle G, Linney A, Reilly G, Edwards SG.

HIV Med. 2009 Jul;10(6):351-5. doi: 10.1111/j.1468-1293.2009.00694.x. Epub 2009 Mar 11.

PMID:
19490181
15.

Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.

Lonergan JT, McComsey GA, Fisher RL, Shalit P, File TM Jr, Ward DJ, Williams VC, Hessenthaler SM, Lindsey L, Hernandez JE; ESS40010 (TARHEEL) Study Team.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):935-42.

PMID:
15220700
16.

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.

Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L; ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):139-47.

PMID:
17106274
17.

Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.

van der Valk M, Casula M, Weverlingz GJ, van Kuijk K, van Eck-Smit B, Hulsebosch HJ, Nieuwkerk P, van Eeden A, Brinkman K, Lange J, de Ronde A, Reiss P.

Antivir Ther. 2004 Jun;9(3):385-93.

PMID:
15259901
18.

Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.

Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, Zuccotti G, Mora S.

Antivir Ther. 2007;12(3):297-302.

PMID:
17591019
19.
20.

Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.

Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP.

J Int AIDS Soc. 2013 Nov 19;16:18794. doi: 10.7448/IAS.16.1.18794.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk